Table 3.
Effect of iron deficiency treatment (scheduled subgroup analysis)
| n | Patients with ID treated in hepcidin arm (n = 53) | n | Patients with ID not treated in control arm (n = 102) | p | |
|---|---|---|---|---|---|
| Primary outcome | |||||
| Post-ICU LOS (days) | 53 | 42 (16; 90) | 102 | 29 (11; 90) | 0.37 |
| Secondary outcomes | |||||
| Number of days alive at home at day 90 | 53 | 50 (0; 76) | 102 | 61 (0; 82) | 0.21 |
| Day 15 visit | |||||
| Day 15 Hb (g/dL) | 40 | 10.7 ± 1.6 | 59 | 10.4 ± 1.4 | 0.24 |
| Day 15 hepcidin (µg/L) | 19 | 35.7 (23.0; 53.7) | 31 | 18.0 (7.6; 44.0) | 0.04 |
| Day 30 visit | |||||
| Fatigue (scale 1–10) | 39 | 5.0 (3.0; 6.0) | 61 | 6.0 (3.0; 7.0) | 0.13 |
| MFI-20 | |||||
| General fatigue (score 9–45) | 40 | 28 (22; 31) | 63 | 26 (18; 30) | 0.33 |
| Mental fatigue (score 6–30) | 40 | 25 (20; 28) | 63 | 25 (20; 28) | 0.75 |
| Reduced activity (score 3–15) | 40 | 8 (6;10) | 63 | 8 (6;11) | 0.66 |
| Reduced motivation (score 2–10) | 40 | 8.(6;10) | 63 | 8 (6; 10) | 0.24 |
| Mortality | |||||
| Death at day 90 | 53 | 2 (3.8) | 102 | 17 (16.7) | 0.02 |
Data are expressed as mean ± SD, median(Q1;Q3) or n(%). We compared the outcomes of patient with iron deficiency (ID, defined as an hepcidin concentration < 41 µg/L) treated in the hepcidin arm to the patients with ID not treated in the control arm
Italics were used to indicate sub-headings in the tables and p-values
ICU intensive care unit, LOS length of stay, MFI-20 multidimensional fatigue inventory, Hb hemoglobin
* Absolute risk difference